Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2003 Oct 17:1:55.
doi: 10.1186/1477-7525-1-55.

Validation of the Rheumatoid and Arthritis Outcome Score (RAOS) for the lower extremity

Ann B I Bremander  1 , Ingemar F Petersson, Ewa M Roos
Affiliations

Validation of the Rheumatoid and Arthritis Outcome Score (RAOS) for the lower extremity

Ann B I Bremander et al. Health Qual Life Outcomes. .

Abstract

Background: Patients with inflammatory joint diseases tend due to new treatments to be more physically active; something not taken into account by currently used outcome measures. The Rheumatoid and Arthritis Outcome Score (RAOS) is an adaptation of the Knee injury and Osteoarthritis Outcome Score (KOOS) and evaluates functional limitations of importance to physically active people with inflammatory joint diseases and problems from the lower extremities. The aim of the study was to test the RAOS for validity, reliability and responsiveness.

Methods: 119 in-patients with inflammatory joint disease (51% RA) admitted to multidisciplinary care, mean age 56 (+/-13), 73% women, mean disease duration 18 (+/-14) yr were consecutively enrolled. They all received the RAOS, the SF-36, the HAQ and four subscales of the AIMS2 twice during their stay for test of validity and responsiveness. Test-retest reliability of the RAOS questionnaire was calculated on 52 patients using the first or second administration and an additional mailed questionnaire.

Results: The RAOS met set criteria of reliability and validity. The random intraclass correlation coefficient (ICC 2,1) for the five subscales ranged from 0.76 to 0.92, indicating that individual comparisons were possible except for the subscale Sport and Recreation Function. Inter-item correlation measured by Cronbach's alpha ranged from 0.78 to 0.95. When measuring construct validity the highest correlations occurred between subscales intended to measure similar constructs. Change over time (24 (+/- 7) days) due to multidisciplinary care was significant for all subscales (p < 0.001). The effect sizes ranged from 0.30-0.44 and were considered small to medium. All the RAOS subscales were more responsive than the HAQ. Some of the SF-36 subscales and the AIMS2 subscales were more responsive than the RAOS subscales.

Conclusion: It is possible to adapt already existing outcome measures to assess other groups with musculoskeletal difficulties in the lower extremity. The RAOS is a reliable, valid and responsive outcome instrument for assessment of multidisciplinary care. To fully validate the RAOS further studies are needed in other populations.

PubMed Disclaimer

Figures

Figure 1
Figure 1
The adaptation and validation process of the Rheumatoid Arthritis Outcome Score (RAOS).
Figure 2
Figure 2
Bland and Altman plots for the five subscales.
Figure 3
Figure 3
Effect size after intervention multidiscipline care for the five dimensions of the RAOS and corresponding dimensions of SF-36, HAQ and AIMS2.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Benedek Thomas G. History of the Rheumatic Diseases. In: John H Klippel, editor. Primer on the Rheumatic Diseases. 11. Atlanta, Georgia, Arthritis Foundation; 1997.
    1. Geborek P, Crnkic M, Petersson IF, Saxne T. Etanercept, infliximab, and leflunomide in established rheumatoid arthritis: clinical experience using a structured follow up programme in southern Sweden. Ann Rheum Dis. 2002;61:793–798. doi: 10.1136/ard.61.9.793. - DOI - PMC - PubMed
    1. Jones G, Halbert J, Crotty M, Shanahan EM, Batterham M, Ahern M. The effect of treatment on radiological progression in rheumatoid arthritis: a systematic review of randomized placebo-controlled trials. Rheumatology (Oxford) 2003;42:6–13. doi: 10.1093/rheumatology/keg036. - DOI - PubMed
    1. Pincus T, Ferraccioli G, Sokka T, Larsen A, Rau R, Kushner I, Wolfe F. Evidence from clinical trials and long-term observational studies that disease-modifying anti-rheumatic drugs slow radiographic progression in rheumatoid arthritis: updating a 1983 review. Rheumatology (Oxford) 2002;41:1346–1356. doi: 10.1093/rheumatology/41.12.1346. - DOI - PubMed
    1. Guillemin F. Functional disability and quality-of-life assessment in clinical practice. Rheumatology (Oxford) 2000;39 Suppl 1:17–23. - PubMed

Publication types